U.S. Bispecific Antibodies Market (2025 - 2033) Size, Share & Trends Analysis Report By Type (Inflammatory & Autoimmune Disorders, Cancer), And Segment Forecasts

U.S. Bispecific Antibodies Market Summary

The U.S. bispecific antibodies market size was estimated at USD 11.78 billion in 2024 and is projected to reach USD 271.95 billion by 2033, growing at a CAGR of 40.1% from 2025 to 2033. The U.S. bispecific antibodies industry is undergoing remarkable growth, driven by the rising burden of cancer and autoimmune diseases and a strong demand for therapies with more precise targeting.

A Nature Reviews Clinical Oncology article (2024) states that over 200 bispecific antibodies are in preclinical or clinical development. Most of these antibodies are designed as immune-cell engagers targeting two antigens, highlighting their potential for precision oncology through dual-target mechanisms.

Furthermore, the rising approval by the U.S. Food and Drug Administration for various bispecific antibodies contributes to the growth of investment in research and development activities. For instance, in May 2025, Pfizer entered a high-value licensing agreement with 3SBio for SSGJ‑707, including a USD1.25 billion upfront payment and up to USD 4.8 billion in milestone-based payouts. Similarly, in June 2025, Bristol Myers Squibb partnered with BioNTech in a deal worth up to USD 11.1 billion for the co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 for various solid tumor types, comprising USD 1.5 billion upfront, USD 2 billion in guaranteed payments, and as much as USD 7.6 billion in additional development, regulatory, and commercial milestones.

In the U.S., bispecific antibodies are becoming increasingly popular due to the rising number of cancer cases nationwide. A 2024 study published by the American Society of Hematology reported on 564 patients with relapsed or refractory multiple myeloma. Out of these patients, 202 were treated with bispecific antibodies, including teclistamab (91%), talquetamab (14%), and elranatamab (3%). The adoption of these treatments grew dramatically, from just one patient treated in 2022 to 45% of eligible patients in 2023 and reached 54% by mid-2024. This swift adoption corresponds with the FDA approvals of teclistamab in October 2022 and elranatamab in August 2023.

Type Insights

The cancer segment led the market with the largest revenue share of 80.8% in 2024 and is expected to grow at the fastest CAGR over the forecast period. The growth of this segment is primarily driven by the rising prevalence of hard-to-treat malignancies and increasing demand for precision-targeted therapies.

In 2024, the American Cancer Society estimated that the number of new cancer cases and deaths in the U.S., based on data collected by central cancer registries and the National Center for Health Statistics, accounted for approximately 2,001,140 new cancer cases and 611,720 cancer deaths were projected to occur in the U.S. Bispecific antibodies offer a unique dual-targeting mechanism that enhances efficacy and reduces resistance compared to conventional treatments. Supportive regulatory pathways, including fast-track and accelerated approvals, are enabling faster market entry for oncology-focused bispecifics. In parallel, robust R&D pipelines and expanding clinical trial activity are reinforcing innovation in solid tumors and hematologic cancers.

For instance, in June 2024, AbbVie announced that the U.S Food and Drug Administration approved EPKINLY as the first and only T-Cell engaging bispecific antibody administered simultaneously for the treatment of adults with relapsed or refractory follicular lymphoma, post 2 or more lines of prior therapy.

The inflammatory and autoimmune disorders segment is expected to grow at a significant CAGR during the forecast period. This segment is gaining momentum owing to the complex nature of these diseases, which often involve multiple immune pathways. Bispecifics offer a targeted approach by simultaneously modulating two disease-relevant molecules, improving therapeutic precision and efficacy.

Key U.S. Bispecific Antibodies Company Insights

Some of the key players in the U.S. bispecific antibodies industry include Amgen, Roche, Genentech, and others.

• Roche is one of the key players in the bispecific antibodies market, with a strong focus on oncology and immunotherapy. The company has developed several CD3-based bispecific antibodies that redirect T-cells to attack cancer cells, including approved treatments for blood cancers.

Recent Developments

• In December 2024, Roche announced that the U.S. Food and Drug Administration (FDA) accepted the company’s supplemental Biologics License Application for Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx).

U.S. Bispecific Antibodies Market Report Scope

U.S. Bispecific Antibodies Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. bispecific antibodies market report based on type:

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Inflammatory & Autoimmune Disorders

  • Cancer

  • Others